PT  - JOURNAL ARTICLE
AU  - Greene, Charlotte R L
AU  - Ward-Penny, Hanna
AU  - Ioannou, Marianna F
AU  - Wild, Sarah H
AU  - Wu, Honghan
AU  - Smith, Daniel J
AU  - Jackson, Caroline A
TI  - Antidepressant and antipsychotic drug prescribing and complications of diabetes: a systematic review of observational studies
AID  - 10.1101/2023.01.27.23285097
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.27.23285097
4099  - http://medrxiv.org/content/early/2023/01/28/2023.01.27.23285097.short
4100  - http://medrxiv.org/content/early/2023/01/28/2023.01.27.23285097.full
AB  - Aims Psychotropic medication may be associated with adverse effects, particularly in people with diabetes. We conducted a systematic review of observational studies investigating the association between antidepressant or antipsychotic drug prescribing and diabetes outcomes.Methods We systematically searched PubMed, EMBASE, and PsycINFO to 15th August 2022 to identify eligible studies. We used the Newcastle-Ottawa scale to assess study quality and performed a narrative synthesis.Results We included 18 studies, 14 reporting on antidepressants and four on antipsychotics. There were 11 cohort studies, one self-controlled before and after study, two case-control studies, and four cross-sectional studies, of variable quality and highly heterogeneous in terms of study population, exposure definition and outcome analysed. Antidepressant prescribing may be associated with increased risk of macrovascular outcomes, whilst evidence on antidepressant and antipsychotic prescribing and glycaemic control was mixed. Few studies reported on microvascular complications and cardiometabolic factors other than glycaemic control and just one study reported on antipsychotics and diabetes complications.Conclusions There has been little study of antidepressant and antipsychotic drug prescribing in relation to diabetes outcomes. Further, more methodologically robust, research is needed to inform and enhance antidepressant and antipsychotic drug prescribing and monitoring practices in people with diabetes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript